Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Depreciation and Depletion (2018 - 2025)

IGC Pharma (IGC) has disclosed Depreciation and Depletion for 12 consecutive years, with $105000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Depreciation and Depletion fell 27.59% to $105000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $512000.0, a 10.65% decrease, with the full-year FY2025 number at $567000.0, up 0.71% from a year prior.
  • Depreciation and Depletion was $105000.0 for Q3 2025 at IGC Pharma, down from $127000.0 in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $200000.0 in Q1 2022 to a low of -$49000.0 in Q1 2023.
  • A 5-year average of $135000.0 and a median of $144000.0 in 2024 define the central range for Depreciation and Depletion.
  • Peak YoY movement for Depreciation and Depletion: plummeted 124.5% in 2023, then skyrocketed 397.96% in 2024.
  • IGC Pharma's Depreciation and Depletion stood at $117000.0 in 2021, then soared by 35.04% to $158000.0 in 2022, then fell by 11.39% to $140000.0 in 2023, then grew by 2.86% to $144000.0 in 2024, then dropped by 27.08% to $105000.0 in 2025.
  • Per Business Quant, the three most recent readings for IGC's Depreciation and Depletion are $105000.0 (Q3 2025), $127000.0 (Q2 2025), and $136000.0 (Q1 2025).